Important Interactions of Immunosuppressants With Experimental Therapies for Novel Coronavirus Disease (COVID-19) : How to Act
| Errataetall: |
CommentOn: N Engl J Med. 2020 May 7;382(19):1787-1799. - PMID 32187464 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:42 |
|---|---|
| Enthalten in: |
Therapeutic drug monitoring - 42(2020), 4 vom: 01. Aug., Seite 652-653 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Zijp, Tanja R [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
2494G1JF75 |
|---|
| Anmerkungen: |
Date Completed 27.07.2020 Date Revised 07.12.2022 published: Print CommentOn: N Engl J Med. 2020 May 7;382(19):1787-1799. - PMID 32187464 Citation Status MEDLINE |
|---|
| doi: |
10.1097/FTD.0000000000000766 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM310155657 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM310155657 | ||
| 003 | DE-627 | ||
| 005 | 20231225135457.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1097/FTD.0000000000000766 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1033.xml |
| 035 | |a (DE-627)NLM310155657 | ||
| 035 | |a (NLM)32433189 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Zijp, Tanja R |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Important Interactions of Immunosuppressants With Experimental Therapies for Novel Coronavirus Disease (COVID-19) |b How to Act |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 27.07.2020 | ||
| 500 | |a Date Revised 07.12.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a CommentOn: N Engl J Med. 2020 May 7;382(19):1787-1799. - PMID 32187464 | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Letter | |
| 650 | 4 | |a Comment | |
| 650 | 7 | |a Immunosuppressive Agents |2 NLM | |
| 650 | 7 | |a Lopinavir |2 NLM | |
| 650 | 7 | |a 2494G1JF75 |2 NLM | |
| 650 | 7 | |a Ritonavir |2 NLM | |
| 650 | 7 | |a O3J8G9O825 |2 NLM | |
| 700 | 1 | |a Toren-Wielema, Martha L |e verfasserin |4 aut | |
| 700 | 1 | |a Nannan Panday, Prashant V |e verfasserin |4 aut | |
| 700 | 1 | |a Kosterink, Jos G W |e verfasserin |4 aut | |
| 700 | 1 | |a Berger, Stefan P |e verfasserin |4 aut | |
| 700 | 1 | |a Touw, Daan J |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Therapeutic drug monitoring |d 1993 |g 42(2020), 4 vom: 01. Aug., Seite 652-653 |w (DE-627)NLM000962295 |x 1536-3694 |7 nnns |
| 773 | 1 | 8 | |g volume:42 |g year:2020 |g number:4 |g day:01 |g month:08 |g pages:652-653 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1097/FTD.0000000000000766 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 42 |j 2020 |e 4 |b 01 |c 08 |h 652-653 | ||